Aggressive Low-Density Lipoprotein Cholesterol Lowering Soon After Acute Coronary Syndrome: Should We Hit Early and Hit Hard?

Recent studies have shown that adding a PCSK 9 inhibiting antibody to the medical regimen soon after an ACS event dramatically lowers LDL-C with a decrease in coronary plaque size and a more stable plaque phenotype. However, the effect of such a regimen on clinical outcome remains to be proven.